菜单

Panjiva_research_logo

Convatec’s diabetes growth in Q3 may be reversing in October

Coronavirus 428 Earnings 489 Health Care 257 U.S. 4625

Convatec announced Q3’20 revenues that improved by 6.5% year over year and expects to “deliver growth at the high end of our guidance range” even as the medical supplies maker found that “COVID continued to drive less predictable demand” according to CEO Karim Bitar. U.S. seaborne imports linked to the firm climbed 12.0% year over year in September and by a further 13.4% in the first three weeks of October. There’s been a marked division in performance at the product line though with cannulae and catheter imports, used in diabetes treatment, rising by 239% in Q3’20 while ostomy applianc...

Copyright © 2020 Panjiva Supply Chain Intelligence, a product offering from S&P Global Market Intelligence Inc. All rights reserved.